2021-11-30

Proud to Attend ISPOR Europe 2021 Virtual Conference!

PeriPharm is proud to attend and present some collaborations at the ISPOR Europe 2021 virtual conference which will be held from November 30 to December 3.
  • Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Gu C, Bui CN. Venetoclax Combination Therapies Show Significant Improvements in Overall Survival and Remission in Treatment-Naïve Patients with AML Who Are Ineligible for Intensive Chemotherapy: A Network Meta-Analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSC35), December 2021, Copenhagen, Denmark (virtual meeting) link
  • Pratz K, Lachaine J, Suh HS, Li X, Schuh AC, Chai X, Xie J, Yin L, Bui CN. Health State Utilities for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSB357), December 2021), Copenhagen, Denmark (virtual meeting) link
  • Schuh AC, Pratz K, Lachaine J, Suh HS, Li X, Chai X, Xie J, Gu C, Bui CN. Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (pp POSA49), Copenhagen, Denmark (virtual meeting) link